Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Comparative Effectiveness and Safety of Pertuzumab Plus Trastuzumab vs Trastuzumab as First-line Treatment for Advanced HER2-positive Breast Cancer: A Target Trial Emulation Study

NCT07829900 is registered in ClinicalTrials.gov with Xin Li as lead sponsor.

NCT NCT07829900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07829900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Comparative Effectiveness and Safety of Pertuzumab Plus Trastuzumab vs Trastuzumab as First-line Treatment for Advanced HER2-positive Breast Cancer: A Target Trial Emulation Study
Lead sponsor
Xin Li
Phase
Observational
Overall status
Completed
Start date
April 20, 2020
Completion date
December 31, 2024
Enrollment
2,250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, her2-positive breast cancer